Development of tuberculosis vaccines in clinical trials: Current status
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Development of tuberculosis vaccines in clinical trials: Current status
Authors
Keywords
-
Journal
SCANDINAVIAN JOURNAL OF IMMUNOLOGY
Volume 88, Issue 4, Pages e12710
Publisher
Wiley
Online
2018-08-29
DOI
10.1111/sji.12710
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The role of the Technical Review Panel of the Global Fund to Fight HIV/AIDS, Tuberculosis and Malaria: an analysis of grant recommendations
- (2018) Guido Schmidt-Traub HEALTH POLICY AND PLANNING
- Time for high-burden countries to lead the tuberculosis research agenda
- (2018) Madhukar Pai PLOS MEDICINE
- Observational study to estimate the changes in the effectiveness of bacillus Calmette–Guérin (BCG) vaccination with time since vaccination for preventing tuberculosis in the UK
- (2017) Punam Mangtani et al. HEALTH TECHNOLOGY ASSESSMENT
- Novel approaches to tuberculosis vaccine development
- (2017) Stefan H.E. Kaufmann et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- HLA-E Presents Glycopeptides from the Mycobacterium tuberculosis Protein MPT32 to Human CD8+ T cells
- (2017) Melanie J. Harriff et al. Scientific Reports
- Enhanced control of Mycobacterium tuberculosis extrapulmonary dissemination in mice by an arabinomannan-protein conjugate vaccine
- (2017) Rafael Prados-Rosales et al. PLoS Pathogens
- The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis
- (2017) Keertan Dheda et al. Lancet Respiratory Medicine
- Comprehensive definition of human immunodominant CD8 antigens in tuberculosis
- (2017) Deborah A. Lewinsohn et al. npj Vaccines
- The potential impact of BCG vaccine supply shortages on global paediatric tuberculosis mortality
- (2016) Rebecca C. Harris et al. BMC Medicine
- IFN-γ and IgA against non-methylated heparin-binding hemagglutinin as markers of protective immunity and latent tuberculosis: Results of a longitudinal study from an endemic setting
- (2016) Mulugeta Belay et al. JOURNAL OF INFECTION
- Vaccination Against Tuberculosis With Whole-Cell Mycobacterial Vaccines
- (2016) Thomas J. Scriba et al. JOURNAL OF INFECTIOUS DISEASES
- Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study
- (2016) Patrick Nguipdop-Djomo et al. LANCET INFECTIOUS DISEASES
- BCG vaccination: a long-lasting protection against tuberculosis? – Authors' reply
- (2016) Patrick Nguipdop-Djomo et al. LANCET INFECTIOUS DISEASES
- MR1-restricted mucosal-associated invariant T (MAIT) cells respond to mycobacterial vaccination and infection in nonhuman primates
- (2016) J M Greene et al. Mucosal Immunology
- Global Efforts in the Development of Vaccines for Tuberculosis: Requirements for Improved Vaccines AgainstMycobacterium tuberculosis
- (2016) P. Méndez-Samperio SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- Alternative BCG delivery strategies improve protection against Mycobacterium tuberculosis in non-human primates: Protection associated with mycobacterial antigen-specific CD4 effector memory T-cell populations
- (2016) S. Sharpe et al. TUBERCULOSIS
- Novel approaches to preclinical research and TB vaccine development
- (2016) Kenneth Barry Walker et al. TUBERCULOSIS
- Immunopathogenesis of tuberculosis and novel mechanisms of vaccine activity
- (2016) Lewis K. Schrager et al. TUBERCULOSIS
- Antibodies and tuberculosis
- (2016) Ashley J. Jacobs et al. TUBERCULOSIS
- Adenovirus type 35-vectored tuberculosis vaccine has an acceptable safety and tolerability profile in healthy, BCG-vaccinated, QuantiFERON ® -TB Gold (+) Kenyan adults without evidence of tuberculosis
- (2016) Douglas S. Walsh et al. VACCINE
- Mucosal BCG Vaccination Induces Protective Lung-Resident Memory T Cell Populations against Tuberculosis
- (2016) Carolina Perdomo et al. mBio
- T-cell activation is an immune correlate of risk in BCG vaccinated infants
- (2016) Helen A. Fletcher et al. Nature Communications
- Heterologous boosting with recombinant VSV-846 in BCG-primed mice confers improved protection against Mycobacterium infection
- (2016) Ming Zhang et al. Human Vaccines & Immunotherapeutics
- Patients with Tuberculosis Have a Dysfunctional Circulating B-Cell Compartment, Which Normalizes following Successful Treatment
- (2016) Simone A. Joosten et al. PLoS Pathogens
- Tuberculosis
- (2016) Madhukar Pai et al. Nature Reviews Disease Primers
- Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens
- (2016) Niels Peter H. Knudsen et al. Scientific Reports
- B cells and antibodies in the defense againstMycobacterium tuberculosisinfection
- (2015) Jacqueline M. Achkar et al. IMMUNOLOGICAL REVIEWS
- Pulmonary but Not Subcutaneous Delivery of BCG Vaccine Confers Protection to Tuberculosis-Susceptible Mice by an Interleukin 17–Dependent Mechanism
- (2015) Nacho Aguilo et al. JOURNAL OF INFECTIOUS DISEASES
- Enhanced and durable protective immune responses induced by a cocktail of recombinant BCG strains expressing antigens of multistage of Mycobacterium tuberculosis
- (2015) Jinping Liang et al. MOLECULAR IMMUNOLOGY
- The balance between protective and pathogenic immune responses in the TB-infected lung
- (2015) Ian M Orme et al. NATURE IMMUNOLOGY
- Tuberculosis vaccines: Time for a global strategy
- (2015) Stefan H. E. Kaufmann et al. Science Translational Medicine
- First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
- (2015) Angelique Kany Kany Luabeya et al. VACCINE
- Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial
- (2015) François Spertini et al. Lancet Respiratory Medicine
- Vaccine against tuberculosis: what’s new?
- (2014) Carlotta Montagnani et al. BMC INFECTIOUS DISEASES
- Tuberculosis in BRICS: challenges and opportunities for leadership within the post-2015 agenda
- (2014) Jacob Creswell et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Tuberculosis among migrant populations in the European Union and the European Economic Area
- (2014) Anna Odone et al. EUROPEAN JOURNAL OF PUBLIC HEALTH
- Multidrug-resistant tuberculosis around the world: what progress has been made?
- (2014) D. Falzon et al. EUROPEAN RESPIRATORY JOURNAL
- The BCG replacement vaccine VPM1002: from drawing board to clinical trial
- (2014) Stefan HE Kaufmann et al. Expert Review of Vaccines
- Protection against Mycobacterium leprae Infection by the ID83/GLA-SE and ID93/GLA-SE Vaccines Developed for Tuberculosis
- (2014) Malcolm S. Duthie et al. INFECTION AND IMMUNITY
- Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial
- (2014) Klaus Reither et al. PLoS One
- Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries
- (2014) G. M. Knight et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial
- (2014) Olubukola T. Idoko et al. TUBERCULOSIS
- Induction and Regulation of T-Cell Immunity by the Novel Tuberculosis Vaccine M72/AS01 in South African Adults
- (2013) Cheryl L. Day et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Protection by BCG Vaccine Against Tuberculosis: A Systematic Review of Randomized Controlled Trials
- (2013) Punam Mangtani et al. CLINICAL INFECTIOUS DISEASES
- A Randomized, Controlled Dose-Finding Phase II Study of the M72/AS01 Candidate Tuberculosis Vaccine in Healthy PPD-Positive Adults
- (2013) Jaime Montoya et al. JOURNAL OF CLINICAL IMMUNOLOGY
- ESAT-6 (EsxA) and TB10.4 (EsxH) Based Vaccines for Pre- and Post-Exposure Tuberculosis Vaccination
- (2013) Truc Hoang et al. PLoS One
- Risk of Progression to Active Tuberculosis Following Reinfection With Mycobacterium tuberculosis
- (2012) Jason R. Andrews et al. CLINICAL INFECTIOUS DISEASES
- Bioinformatic and Empirical Analysis of Novel Hypoxia-Inducible Targets of the Human Antituberculosis T Cell Response
- (2012) H. P. Gideon et al. JOURNAL OF IMMUNOLOGY
- Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines
- (2012) Satria A. Prabowo et al. MEDICAL MICROBIOLOGY AND IMMUNOLOGY
- Unknown
- (2012) Sayma Rahman et al. MOLECULAR MEDICINE
- Efficacy of Mycobacterium indicus pranii Immunotherapy as an Adjunct to Chemotherapy for Tuberculosis and Underlying Immune Responses in the Lung
- (2012) Ankan Gupta et al. PLoS One
- Protective efficacy of Mycobacterium indicus pranii against tuberculosis and underlying local lung immune responses in guinea pig model
- (2012) Ankan Gupta et al. VACCINE
- Improved CD4+ T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: A randomized trial
- (2012) Isabel Leroux-Roels et al. VACCINE
- Vaccines against Tuberculosis: Where Are We and Where Do We Need to Go?
- (2012) Tom H. M. Ottenhoff et al. PLoS Pathogens
- Current and novel approaches to vaccine development against tuberculosis
- (2012) Mark J. Cayabyab et al. Frontiers in Cellular and Infection Microbiology
- First in humans: A new molecularly defined vaccine shows excellent safety and strong induction of long-livedMycobacterium tuberculosis-specific Th1-cell like responses
- (2011) Tom H. M. Ottenhoff et al. Human vaccines & immunotherapeutics
- A multistage tuberculosis vaccine that confers efficient protection before and after exposure
- (2011) Claus Aagaard et al. NATURE MEDICINE
- Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection
- (2011) Jaap T. van Dissel et al. VACCINE
- Mycobacterium vaccae vaccine to prevent tuberculosis in high risk people: A meta-analysis
- (2010) Xiao-yan Yang et al. JOURNAL OF INFECTION
- A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis
- (2010) S. Bertholet et al. Science Translational Medicine
- Ag85B–ESAT-6 adjuvanted with IC31® promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers
- (2010) Jaap T. van Dissel et al. VACCINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now